Hepa Thera HT-101 Project Summary Meeting Successfully Concludes

On September 28, 2024, the summary meeting for the "Phase I Clinical Study of HT-101 Injection in Healthy Volunteers and Patients with Chronic Hepatitis B Virus Infection," sponsored by Hepa Thera, was successfully held in Beijing.

The meeting was chaired by Professor Jia Jidong from the Liver Disease Center of Beijing Friendship Hospital, Capital Medical University, and Professor Dong Ruihua from the Research Ward, with researchers from various centers across the country participating online and offline to summarize and discuss the interim results of the Phase I clinical study of the HT-101 project.

The conference officially commenced with opening remarks from Professors Jia Jidong, Dong Ruihua, and President Ma Yanqin of Hepa Thera.

At this meeting, Beijing Fosun Pharmaceutical, as the CRO company for this trial, had its representatives review the clinical Phase I study journey of HT-101 injection and present the clinical trial data and results. The attending experts engaged in a heated discussion of these data and results, and fully affirmed the clinical outcomes, especially the efficacy data of patients in the Ib phase.

Professor Niu Junqi from Jilin University, when discussing the data of Ib phase patients, considered HT-101 to be one of the most significant drugs observed in reducing hepatitis B surface antigen. Professor Jia Jidong from Beijing Friendship Hospital, Capital Medical University, stated that the safety of HT-101 injection is very good, and its reduction amplitude and duration of action on hepatitis B surface antigen are also impressive.

The high praise and affirmation from the participating experts for the clinical results further strengthened the confidence of all parties in the subsequent functional cure of chronic hepatitis B.

In addition, the meeting also summarized the management experience of the clinical research centers during the project. Professor Wang Yanbin from Beijing Ditan Hospital, Capital Medical University, and Professor Qi Xun from the Shanghai Public Health Clinical Center shared their experiences in aspects such as subject enrollment and trial quality management.

Finally, to recognize the contributions of the participating clinical centers to the successful completion of the HT-101 project's Phase I clinical study, Hepa Thera awarded trophies to representatives from each center.